<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bladder Cancer Clinical Trials</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        @media (max-width: 768px) {
            .responsive-table {
                display: block;
                width: 100%;
                overflow-x: auto;
            }
        }
    </style>
</head>
<body class="bg-gray-50 p-6">
    <div class="max-w-[95%] mx-auto bg-white rounded-lg shadow-lg overflow-hidden">
        <h1 class="text-2xl font-bold text-gray-800 p-6 border-b border-gray-200">First-Line Bladder Cancer Clinical Trials</h1>
        <div class="responsive-table">
            <table class="min-w-full divide-y divide-gray-200">
                <thead class="bg-gray-50">
                    <tr>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider whitespace-nowrap">Start Date</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider whitespace-nowrap">Study Name or NCT</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider whitespace-nowrap">Company Sponsor</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider whitespace-nowrap">N (enrollment)</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Specific Patient Population</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Active Arm</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Control Arm</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider whitespace-nowrap">Primary Endpoints</th>
                        <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Comments</th>
                    </tr>
                </thead>
                <tbody class="bg-white divide-y divide-gray-200">
                    <tr class="hover:bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Nov 2, 2015</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">DANUBE (NCT02516241)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">AstraZeneca</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">1032</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Untreated unresectable Stage IV urothelial carcinoma; included both cisplatin-eligible and -ineligible patients (carboplatin allowed)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Durvalumab monotherapy; Durvalumab + Tremelimumab</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Platinum-based chemotherapy (gemcitabine + cisplatin or carboplatin)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">OS (PD-L1–high subgroup); OS (all patients)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Dual checkpoint immunotherapy vs chemo. Co-primary OS endpoints were not met – neither durvalumab alone nor with tremelimumab improved survival vs chemo.</td>
                    </tr>
                    <tr class="hover:bg-gray-50 bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Apr 2016</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">JAVELIN Bladder 100 (NCT02603432)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Pfizer / Merck KGaA</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">700</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Unresectable locally advanced or metastatic UC with no progression after 4–6 cycles of first-line platinum (cisplatin or carboplatin) + gemcitabine chemotherapy</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Avelumab maintenance + best supportive care (BSC)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Best supportive care alone (observation)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">OS</td>
                        <td class="px-6 py-4 text-sm text-gray-900">First trial of switch maintenance immunotherapy after chemotherapy. Demonstrated significantly prolonged OS with maintenance avelumab vs observation, establishing a new standard of care in 1L maintenance.</td>
                    </tr>
                    <tr class="hover:bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Jun 30, 2016</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">IMvigor130 (NCT02807636)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Genentech/Roche</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">1213</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Previously untreated locally advanced or metastatic UC; both cisplatin-eligible and -ineligible patients included (cisplatin or carboplatin per investigator's choice)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Atezolizumab + platinum (cisplatin or carboplatin) + gemcitabine; Atezolizumab monotherapy</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Platinum (cisplatin or carboplatin) + gemcitabine + placebo</td>
                        <td class="px-6 py-4 text-sm text-gray-900">PFS; OS</td>
                        <td class="px-6 py-4 text-sm text-gray-900">First positive Phase 3 combo immunotherapy trial in 1L UC. Atezolizumab + chemo significantly improved PFS vs chemo, but did not yield a significant OS improvement at final analysis. Atezolizumab monotherapy arm showed no OS benefit over chemo, leading to use restricted to PD-L1–high/cis-ineligible patients.</td>
                    </tr>
                    <tr class="hover:bg-gray-50 bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Sept 15, 2016</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">KEYNOTE-361 (NCT02853305)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Merck (MSD)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">1010</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Untreated locally advanced or metastatic urothelial carcinoma; included cisplatin-eligible and -ineligible patients (cisplatin or carboplatin allowed)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Pembrolizumab + platinum (cisplatin or carboplatin) + gemcitabine; Pembrolizumab monotherapy</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Platinum (cisplatin or carboplatin) + gemcitabine (standard chemo)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">PFS; OS</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Three-arm trial (PD-1 monotherapy and combo vs chemo). It failed to show a significant improvement in PFS or OS for the pembrolizumab + chemo arm compared to chemo; consequently the pembrolizumab monotherapy arm was not formally tested for OS superiority. No new approvals stemmed from this negative study.</td>
                    </tr>
                    <tr class="hover:bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Mar 24, 2017</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">CheckMate 901 (NCT03036098)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Bristol Myers Squibb / Ono</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">897</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Previously untreated unresectable or metastatic urothelial carcinoma; trial had cohorts for cisplatin-eligible and cisplatin-ineligible patients</td>
                        <td class="px-6 py-4 text-sm text-gray-900">(a) Nivolumab + cisplatin/gemcitabine (with maintenance nivolumab); (b) Nivolumab + Ipilimumab</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Platinum-based chemotherapy (gemcitabine + cisplatin for eligible, or + carboplatin for ineligible)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">OS; PFS</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Multi-arm study. In cisplatin-eligible patients, nivolumab + chemo significantly improved OS and PFS vs chemo. However, in PD-L1≥1% cisplatin-ineligible patients, nivolumab + ipilimumab did not improve OS compared to chemo. The chemo–immunotherapy combination arm led to regulatory approval, while the dual immunotherapy arm was negative.</td>
                    </tr>
                    <tr class="hover:bg-gray-50 bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Sept 27, 2018</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">NILE (NCT03682068)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">AstraZeneca</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">1246</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Untreated unresectable locally advanced or metastatic urothelial carcinoma; both cisplatin-fit and -unfit patients (cisplatin or carboplatin per eligibility)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Durvalumab + platinum/gemcitabine; Durvalumab + Tremelimumab + platinum/gemcitabine</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Platinum + gemcitabine chemotherapy</td>
                        <td class="px-6 py-4 text-sm text-gray-900">OS (originally in overall and PD-L1 high populations)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Trial of adding immunotherapy (PD-L1 ± CTLA-4) to standard chemo. After initial data, protocol was amended to focus on PD-L1–high patients. Ongoing trial (primary completion expected 2025); no final results yet reported as of 2025.</td>
                    </tr>
                    <tr class="hover:bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">May 29, 2019</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">BeiGene BGB-A317-310 (NCT03967977)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">BeiGene</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">420</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Locally advanced or metastatic urothelial carcinoma with no prior systemic therapy; cisplatin-eligible or -ineligible (must be fit for either cisplatin or carboplatin)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Tislelizumab (PD-1 inhibitor) + platinum (cisplatin or carboplatin) + gemcitabine</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Placebo + platinum (cisplatin or carboplatin) + gemcitabine</td>
                        <td class="px-6 py-4 text-sm text-gray-900">OS</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Global double-blind trial of PD-1 inhibitor from China in 1L UC. Designed to test addition of tislelizumab to platinum/gem chemotherapy vs chemo alone. Trial is ongoing (no results yet).</td>
                    </tr>
                    <tr class="hover:bg-gray-50 bg-gray-50">
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Mar 2020</td>
                        <td class="px-6 py-4 text-sm text-blue-600 font-medium whitespace-nowrap">EV-302 / KEYNOTE-A39 (NCT04223856)</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">Seagen / Astellas + Merck</td>
                        <td class="px-6 py-4 text-sm text-gray-900 whitespace-nowrap">886</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Previously untreated locally advanced or metastatic urothelial carcinoma; regardless of cisplatin eligibility (cisplatin or carboplatin allowed in control arm)</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Enfortumab vedotin (Nectin-4 ADC) + Pembrolizumab</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Platinum (cisplatin or carboplatin) + gemcitabine chemotherapy</td>
                        <td class="px-6 py-4 text-sm text-gray-900">PFS; OS</td>
                        <td class="px-6 py-4 text-sm text-gray-900">Chemo-free novel combination. This trial showed enfortumab vedotin + pembrolizumab significantly improved OS and PFS over standard chemotherapy in first-line advanced bladder cancer. Led to FDA approval (Dec 2023) of the combo as a new first-line option, regardless of cisplatin eligibility.</td>
                    </tr>
                </tbody>
            </table>
        </div>
    </div>
</body>
</html>